1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Geron Corporation

Geron Corporation

GERN
Geron CorporationUS flagNASDAQ Global Select
1.23
USD
+0.03
- -
790.24MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.01
0.01
0.23
0.04
0.01
0.01
- -
- -
- -
- -
- -
0.12
0.28
0.31
Basic EPS, GAAP
-0.3
-0.23
- -
-0.19
-0.18
-0.15
-0.36
-0.28
-0.35
-0.37
-0.32
-0.27
-0.13
-0.1
Free Cash Flow per Basic Share
-0.29
0.06
-0.15
-0.12
-0.13
-0.12
-0.23
-0.25
-0.29
-0.34
-0.3
-0.34
-0.17
-0.17
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.46
0.83
0.9
0.77
0.65
0.95
0.68
0.68
0.39
0.2
0.46
0.46
0.35
0.34
Tangible Book Value per Share
0.46
0.83
0.9
0.77
0.65
0.95
0.68
0.68
0.39
0.2
0.46
0.46
0.35
0.34
Basic Weighted Avg Shares
128
154
158
159
159
177
190
271
328
381
571
646
667
669
Sales/Revenue/Turnover
1
1
36
6
1
1
- -
- -
1
1
- -
77
184
205
Operating Margin (%)
-2,922.53
-3,149.35
2.05
-497.34
-2,746.95
-2,914.92
-15,761.96
-30,400.4
-8,183.7
-23,246.64
-81,832.91
-225.64
-28.04
-17.25
Depreciation Expense
- -
- -
- -
- -
- -
- -
1
1
1
1
1
1
1
1
Net Income, GAAP
-38
-36
- -
-30
-28
-27
-69
-76
-116
-142
-184
-175
-84
-68
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-2,991.35
-3,093.67
0.13
-479.34
-2,621.22
-2,534.43
-14,901.74
-29,888.14
-8,335.39
-23,808.89
-77,690.72
-226.73
-45.41
-33.05
Working Capital
59
112
109
108
89
159
113
169
142
104
233
403
409
416
LT Debt
- -
- -
- -
- -
- -
- -
2
29
54
34
38
121
121
121
Total Equity
60
131
142
122
104
178
135
211
126
80
248
280
226
219
Return on Invested Capital (%)
- -
- -
0.55
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
0.1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-52.79
-37.45
0.03
-22.33
-24.69
-19.19
-43.82
-43.7
-68.84
-137.49
-112.29
-66.09
-32.99
-28.28

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
1
1
LT Borrowings
120
120
120
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
640
641
642
Market Capitalization
845
955
822

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
520
499
486
Cash, Cash Equivalents & STI
358
312
301
Accounts Receivable, Net
37
42
52
Inventories
117
133
124
Total Current Liabilities
112
74
70
Payables & Accruals
59
38
33
ST Debt
1
1
1
Deferred Revenue
3
6
7

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.11%
25.36%
-19.42%
Free Cash Flow
24.06%
17.78%
-49.34%
Net Income, GAAP
-6,410.74%
9.63%
-52.17%
Sales/Revenue/Turnover
3,259.14%
6,571.78%
138.83%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1
28
48
77
2025
40
49
47
48
184
2026
52
57
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.09
-0.1
-0.04
-0.04
-0.27
2025
-0.03
-0.02
-0.03
-0.04
-0.13
2026
-0.01
-0.02
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Harout Semerjian
Full Time Employees
258
Sector
Healthcare
Industry
Biotechnology
Address
919 East Hillsdale Boulevard Foster City CA United States of America 94404
IPO Date
Jul 31, 1996
CIK
0000886744
Website
geron.com
Similar Companies
Tissue Regenix Group plc (TRX.L)
Kyntra Bio, Inc. (KYNB)
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS)
Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ)
ISR Immune System Regulation Holding AB (publ) (ISR.ST)
Silexion Therapeutics Ltd. (SLXN)
Business
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company headquartered in Foster City, California and founded in 1990, develops and commercializes telomerase inhibitor therapeutics targeting hematologic malignancies. The company markets RYTELO (imetelstat), a first-in-class telomerase inhibitor indicated for adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia requiring four or more red blood cell units per eight weeks; it explores the broad potential of telomerase inhibition across multiple myeloid hematologic malignancies, including ongoing Phase 3 clinical trials of imetelstat in relapsed/refractory myelofibrosis (IMproveMF trial, NCT04576156) and previously transfusion-dependent anemia in myelodysplastic syndromes (IMerge trial, NCT02598661). Geron operates primarily in the United States with a focus on oncology therapeutics for blood cancers. In November 2024, Geron secured up to $375 million in non-dilutive funding through synthetic royalty financing agreements with Royalty Pharma and Pharmakon Advisors, including an initial $125 million upfront payment for a royalty interest on U.S. net sales of RYTELO to support commercial launch, pipeline advancement, and general corporate purposes. The company reported fourth quarter and full-year 2024 financial results highlighting RYTELO commercialization progress, robust pipeline execution, and increased research and development investments into 2025 for ongoing clinical trials. Geron continues to prioritize global expansion of RYTELO access and telomerase-based therapies without noted acquisitions, partnerships beyond financing, or structural reorganizations in the past two years.

Company News

Company News APIChatGPT

  • globenewswire.com

    Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • prnewswire.com

    Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

  • businesswire.com

    Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

  • globenewswire.com

    Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia

  • gurufocus.com

    Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

  • gurufocus.com

    Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

  • prnewswire.com

    Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

  • prnewswire.com

    Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

  • globenewswire.com

    Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • marketbeat.com

    Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands

  • gurufocus.com

    Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

  • businesswire.com

    Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN

  • marketbeat.com

    Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands

  • gurufocus.com

    Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

  • prnewswire.com

    Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?

  • prnewswire.com

    Kuehn Law Encourages Investors of Geron Corporation to Contact Law Firm

  • globenewswire.com

    Geron to Present at Upcoming Investor Conferences

  • defenseworld.net

    ADAR1 Capital Management LLC Invests $647,000 in Geron Corporation $GERN

  • globenewswire.com

    Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • seekingalpha.com

    Geron Corp: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis